Clinical outcomes of a hydrophobic trifocal diffractive intraocular lens: a literature review.

IF 3.1 3区医学 Q1 MEDICINE, GENERAL & INTERNAL

Frontiers in Medicine Pub Date : 2025-01-22 eCollection Date: 2025-01-01 DOI:10.3389/fmed.2025.1533161

Deborah Ristvedt, Camille Bosc, Vance Thompson

{"title":"Clinical outcomes of a hydrophobic trifocal diffractive intraocular lens: a literature review.","authors":"Deborah Ristvedt, Camille Bosc, Vance Thompson","doi":"10.3389/fmed.2025.1533161","DOIUrl":null,"url":null,"abstract":"<p><p>The aim of this review is to summarize the clinical outcomes reported in patients following the implantation of the hydrophobic diffractive trifocal FineVision HP intraocular lens (IOL). A literature search in PubMed (U.S. National Library of Medicine) was performed to identify publications, both prospective and retrospective, which have reported the clinical outcomes of patients who were implanted with this IOL model after cataract or refractive lens exchange surgeries. A total of 18 clinical studies published between 2019 and 2024 were included in this review. The available data reported in the different clinical publications was analyzed in detail, focusing mainly on refraction, visual acuity, the defocus curve, optical quality, contrast sensitivity, and patient-reported outcome questionnaires. In addition, the adverse events and other measurements reported in some studies were also analyzed. Our review encompassed a total of 1,028 eyes analyzed at different follow-up periods up to a maximum of 24 months. The analysis carried out in this review leads us to conclude that the FineVision HP IOL provides good refractive outcomes and excellent visual performance when implanted.</p>","PeriodicalId":12488,"journal":{"name":"Frontiers in Medicine","volume":"12 ","pages":"1533161"},"PeriodicalIF":3.1000,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11794266/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fmed.2025.1533161","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

The aim of this review is to summarize the clinical outcomes reported in patients following the implantation of the hydrophobic diffractive trifocal FineVision HP intraocular lens (IOL). A literature search in PubMed (U.S. National Library of Medicine) was performed to identify publications, both prospective and retrospective, which have reported the clinical outcomes of patients who were implanted with this IOL model after cataract or refractive lens exchange surgeries. A total of 18 clinical studies published between 2019 and 2024 were included in this review. The available data reported in the different clinical publications was analyzed in detail, focusing mainly on refraction, visual acuity, the defocus curve, optical quality, contrast sensitivity, and patient-reported outcome questionnaires. In addition, the adverse events and other measurements reported in some studies were also analyzed. Our review encompassed a total of 1,028 eyes analyzed at different follow-up periods up to a maximum of 24 months. The analysis carried out in this review leads us to conclude that the FineVision HP IOL provides good refractive outcomes and excellent visual performance when implanted.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Medicine Medicine-General Medicine

CiteScore

5.10

自引率

5.10%

发文量

3710

审稿时长

12 weeks

期刊介绍： Frontiers in Medicine publishes rigorously peer-reviewed research linking basic research to clinical practice and patient care, as well as translating scientific advances into new therapies and diagnostic tools. Led by an outstanding Editorial Board of international experts, this multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide. In addition to papers that provide a link between basic research and clinical practice, a particular emphasis is given to studies that are directly relevant to patient care. In this spirit, the journal publishes the latest research results and medical knowledge that facilitate the translation of scientific advances into new therapies or diagnostic tools. The full listing of the Specialty Sections represented by Frontiers in Medicine is as listed below. As well as the established medical disciplines, Frontiers in Medicine is launching new sections that together will facilitate - the use of patient-reported outcomes under real world conditions - the exploitation of big data and the use of novel information and communication tools in the assessment of new medicines - the scientific bases for guidelines and decisions from regulatory authorities - access to medicinal products and medical devices worldwide - addressing the grand health challenges around the world